Study of two new drugs for advanced solid tumors
Part of Cancer clinical trials.
This trial tests two new injectable drugs for advanced solid tumors, especially kidney, head and neck, cervical, and ovarian cancers. The goal is to see if the combination is safe and if it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced cancer (kidney, head and neck, cervical, or ovarian) that has spread or cannot be removed with surgery.
- You have tried at least one standard treatment (like chemotherapy or immunotherapy) and it didn't work or you couldn't tolerate it.
- You are able to take care of yourself and are up and about more than half the day.
- You have not had chemotherapy or other cancer treatment in the last 4 weeks.
- You do not have serious infections, active autoimmune disease, or untreated hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs, P1101 and P1801, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This trial tests an experimental therapy that combines a new drug (OVV-01) given intravenously and injected directly into tumors, along with another immunotherapy drug (AK112). It's for people with advanced solid tumors who have run out of standard options, and it aims to see if the combination can shrink tumors or slow their growth.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.